Drug Trial Radar · NCT06556966
A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects
Last checked: Nov 19, 2026Latest source record: May 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
Aug 19, 2024
Primary completion
Feb 13, 2025
Study completion Feb 13, 2025
Sponsor
- Lead sponsor
- Luye Pharma Group Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, randomized, double-blind, placebo-controlled, ascending single oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects.
Conditions
- Schizophrenia
- Alzheimer's Disease Psychosis
Interventions
LY03020Drug
LY03020 for one single dose
PlaceboDrug
Placebo for one single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of adverse events (AEs)Time frame: up to144 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing AnDing Hospital Capital Medical University
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.